Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus
- 1 April 1990
- Vol. 8 (2) , 164-168
- https://doi.org/10.1016/0264-410x(90)90141-8
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Immunosuppression of the Antibody Response to Respiratory Syncytial Virus (RSV) by Pre-existing Serum Antibodies: Partial Prevention by Topical Infection of the Respiratory Tract with Vaccinia Virus-RSV RecombinantsJournal of General Virology, 1989
- Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virusVaccine, 1988
- Live viral vaccines for respiratory and enteric tract diseasesVaccine, 1988
- Demonstration that Glycoprotein G Is the Attachment Protein of Respiratory Syncytial VirusJournal of General Virology, 1987
- Cytotoxic T Cell Specificity for Respiratory Syncytial Virus Proteins: Fusion Protein Is an Important Target AntigenJournal of General Virology, 1987
- Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.Molecular and Cellular Biology, 1985
- Live recombinant vaccinia virus protects chimpanzees against hepatitis BNature, 1984
- Experimental respiratory syncytial virus infection of four species of primatesJournal of Medical Virology, 1977
- Respiratory syncytial virus infections in infants: Quantitation and duration of sheddingThe Journal of Pediatrics, 1976
- Quantitative Shedding Patterns of Respiratory Syncytial Virus in InfantsThe Journal of Infectious Diseases, 1975